{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T10:07:25Z","timestamp":1753870045792,"version":"3.41.2"},"reference-count":68,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2021,6,20]],"date-time":"2021-06-20T00:00:00Z","timestamp":1624147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Res &amp; Perspec"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study aimed to investigate the efficacy and safety of sofosbuvir\u2010based therapies for the treatment of cirrhosis from hepatitis C virus (HCV) genotype 2 infection. Data of all consecutive HCV genotype 2 cirrhotic patients who started sofosbuvir\u2010based treatments between January 2015 and March 2017 in eight Italian tertiary hospitals were collected retrospectively. Overall, 273 patients (Child A: 94.5%) were enrolled. In the 194 subjects treated with sofosbuvir\/ribavirin, median initial ribavirin dosage was 13.9\u00a0mg\/kg\/day, and therapy duration was 16\u00a0weeks. Sustained virological response (SVR) rates were 93.8% in intention\u2010to\u2010treat (ITT) and 95.3% in per\u2010protocol (PP) analyses for the 129 treatment\u2010na\u00efve patients, and 96.9% (ITT) and 98.4% (PP) for the 65 treatment\u2010experienced subjects. Adverse events were reported in 142 patients (73.2%), but only 1.5% discontinued treatment. Eighty\u2010eight subjects with treatment\u2010induced anemia (mild: 34.5%, moderate: 7.7%, severe: 3.1%) had to reduce ribavirin dosage, but SVR rates were comparable to the weight\u2010based dose group, both in ITT (95.4% and 94.3%) and PP (97.7% and 95.2%) analyses, respectively. Moreover, ITT and PP SVR rates were similar between shorter (&lt;20\u00a0weeks) (94.1% and 96.0%, respectively) and prolonged (\u226520\u00a0weeks) regimens (95.7% and 96.7%, respectively). SVR rates in the 79 subjects treated with sofosbuvir\/daclatasvir (without ribavirin) were similar (ITT: 96.2%; PP: 97.4%, respectively), without de novo\/worsening anemia. In conclusion, in a real\u2010life study centered on genotype 2 patients with well\u2010compensated cirrhosis, sofosbuvir\u2010based regimens were associated with good SVR and tolerability rates, regardless of previous antiviral treatments, without a significant impact of on treatment ribavirin dose reductions.<\/jats:p>","DOI":"10.1002\/prp2.811","type":"journal-article","created":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T02:15:25Z","timestamp":1624241725000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Sofosbuvir\u2010based therapies in genotype 2 hepatitis C virus cirrhosis: A real\u2010life experience with focus on ribavirin dose"],"prefix":"10.1002","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3338-5416","authenticated-orcid":false,"given":"Carlo","family":"Smirne","sequence":"first","affiliation":[{"name":"Internal Medicine Division Department of Translational Medicine Universit\u00e0 del Piemonte Orientale Novara Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"D'Avolio","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit Department of Medical Sciences University of Torino Turin Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattia","family":"Bellan","sequence":"additional","affiliation":[{"name":"Internal Medicine Division Department of Translational Medicine Universit\u00e0 del Piemonte Orientale Novara Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Gualerzi","sequence":"additional","affiliation":[{"name":"Internal Medicine Division Sant'Andrea Hospital Vercelli Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria G.","family":"Crobu","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Virology Maggiore della Carit\u00e0 Hospital Novara Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Pirisi","sequence":"additional","affiliation":[{"name":"Internal Medicine Division Department of Translational Medicine Universit\u00e0 del Piemonte Orientale Novara Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,6,20]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27259"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2018.02.015"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27950"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.03.025"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-016-9717-6"},{"key":"e_1_2_13_7_1","unstructured":"Italian Association for the Study of the Liver (AISF).AISF guidance document for the rational use of second\u2010generation direct antiviral agents in the categories of patients affected from chronic hepatitis C and eligible for reimbursement in Italy.http:\/\/www.clubepatologiospedalieri.it\/wp\u2010content\/uploads\/2017\/01\/Linee\u2010guida\u2010AISF\u20102015_05_26.pdf. Accessed March 29 2021."},{"issue":"23","key":"e_1_2_13_8_1","first-page":"906","article-title":"The guideline of prevention and treatment for hepatitis C: a 2015 update","volume":"2015","author":"Chinese Society of Hepatology, Chinese Medical Association","year":"2015","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"24","key":"e_1_2_13_9_1","first-page":"169","article-title":"KASL clinical practice guidelines management of hepatitis C: treatment of chronic hepatitis C","volume":"2018","author":"Korean Association for the Study of the Liver (KASL)","year":"2017","journal-title":"Clin Mol Hepatol"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy585"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.5009\/gnl19260"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2009.24.3.203"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31824bf778"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.12695"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2017.0070"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2018.329"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227424"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13069"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12664-018-0921-2"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214854"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214853"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316145"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.07.043"},{"volume-title":"Sovaldi: European public assessment report (EPAR) \u2013 Product Information","author":"European Medicines Agency (EMA)","key":"e_1_2_13_24_1"},{"volume-title":"WHO Global Database on Anaemia. Worldwide Prevalence of Anemia 1993\u20132005","author":"World Health Organization. (WHO)","key":"e_1_2_13_25_1"},{"key":"e_1_2_13_26_1","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","author":"National Kidney Foundation","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(99)00559-3"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1121"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14752"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2018.338"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.12.002"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025110"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajg.2020.09.001"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13246"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/kjm2.12315"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4741-5"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13321"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14615"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199941"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCMA.0000000000000148"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14849"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i44.6551"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2018.09.016"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13056"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25023"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.7812\/TPP\/16-096"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0185728"},{"key":"e_1_2_13_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-311609"},{"key":"e_1_2_13_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.23399"},{"key":"e_1_2_13_50_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.06.071"},{"key":"e_1_2_13_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2019.07.028"},{"key":"e_1_2_13_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2012.01637.x"},{"key":"e_1_2_13_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.12480"},{"key":"e_1_2_13_54_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e31820d35e3"},{"key":"e_1_2_13_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14812"},{"key":"e_1_2_13_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08825"},{"key":"e_1_2_13_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13743"},{"key":"e_1_2_13_58_1","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2020.1758557"},{"key":"e_1_2_13_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14288"},{"key":"e_1_2_13_60_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2984"},{"key":"e_1_2_13_61_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133879"},{"key":"e_1_2_13_62_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158512"},{"key":"e_1_2_13_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2010.01303.x"},{"key":"e_1_2_13_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13036"},{"key":"e_1_2_13_65_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S134818"},{"key":"e_1_2_13_66_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006128"},{"key":"e_1_2_13_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2017.04.012"},{"key":"e_1_2_13_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2016.10.012"},{"key":"e_1_2_13_69_1","doi-asserted-by":"publisher","DOI":"10.1159\/000448824"}],"container-title":["Pharmacology Research &amp; Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.811","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/prp2.811","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.811","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T03:40:18Z","timestamp":1693194018000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/prp2.811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,20]]},"references-count":68,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1002\/prp2.811"],"URL":"https:\/\/doi.org\/10.1002\/prp2.811","archive":["Portico"],"relation":{},"ISSN":["2052-1707","2052-1707"],"issn-type":[{"type":"print","value":"2052-1707"},{"type":"electronic","value":"2052-1707"}],"subject":[],"published":{"date-parts":[[2021,6,20]]},"assertion":[{"value":"2021-04-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00811"}}